Loading...
By Kristin J. Kelley
Edited by André Sofair, MD, MPH
The FDA cleared two tests late last week for guiding treatment decisions in patients with infections.
The agency granted market clearance for a blood test (the PhenoTest BC Kit) that identifies the cause of bacterial or yeast blood infections. By looking at the similarity of the infectious agent's DNA to the DNA of reference bacteria and yeast, the PhenoTest is able to identify 14 different species of bacteria and 2 yeast species in about 1.5 hours and, for some organisms, can provide clinicians with enough information to guide treatment recommendations in about 6.5 hours. (Traditional test results can take 24–48 hours.) The test can also detect whether indicators of antibiotic resistance are present.
Additionally, the FDA allowed for the expanded use of the first procalcitonin test (Vidas Brahms PCT Assay) to help clinicians manage antibiotic treatment in patients with lower respiratory tract infections and sepsis.
The procalcitonin assay is intended for use in hospitals and emergency rooms. High procalcitonin levels can indicate a bacterial infection, and low levels a viral or noninfectious cause.
Antibiotic use in patients who received PCT-guided therapy was significantly decreased, compared with those who received standard therapy in randomized trials.
Comment
LINK(S):
FDA news release about the PhenoTest BC Kit (Free)
FDA news release about the Vidas Brahms PCT Assay (Free)
Background: NEJM Journal Watch Infectious Diseases coverage of procalcitonin testing in critically ill patients (Your NEJM Journal Watch registration required)